↓ Skip to main content

Dove Medical Press

Article Metrics

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder

Overview of attention for article published in Neuropsychiatric Disease and Treatment, May 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter
3 tweeters
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
60 Mendeley
Title
Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
Published in
Neuropsychiatric Disease and Treatment, May 2015
DOI 10.2147/ndt.s65735
Pubmed ID
Authors

Jose Martinez-Raga, Carlos Knecht, Raquel de Alvaro

Abstract

The α2-adrenergic receptor agonist guanfacine, in its extended-release formulation (GXR), is the most recent nonstimulant medication approved in several countries for the treatment of attention-deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive pharmacotherapy to stimulants in children and adolescents. The present paper aims to review comprehensively and critically the pharmacodynamic and pharmacokinetic characteristics and the published evidence on the efficacy and safety profile of GXR in the treatment of ADHD. A comprehensive search of relevant databases (PubMed, Embase, and PsycInfo) was conducted to identify studies published in peer-reviewed journals until January 15, 2015. Though the precise mechanism of action of guanfacine in the treatment of ADHD is not fully understood, it is thought to act directly by enhancing noradrenaline functioning via α2A-adrenoceptors in the prefrontal cortex. Weight-adjusted doses should be used, with a dosing regime on a milligram per kilogram basis, starting at doses in the range 0.05-0.08 mg/kg/day, up to 0.12 mg/kg/day. As evidenced in short-term randomized controlled trials and in long-term open-label extension studies, GXR has been shown to be effective as monotherapy in the treatment of ADHD. Furthermore, GXR has also been found to be effective as adjunctive therapy to stimulant medications in patients with suboptimal responses to stimulants. Many of the adverse reactions associated with GXR, particularly sedation-related effects, were dose-related, transient, mild to moderate in severity, and did not interfere with attention or overall efficacy. There are no reports of serious cardiovascular adverse events associated with GXR alone or in combination with psychostimulants.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
Unknown 59 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 12%
Student > Postgraduate 6 10%
Other 6 10%
Student > Bachelor 6 10%
Student > Master 6 10%
Other 14 23%
Unknown 15 25%
Readers by discipline Count As %
Medicine and Dentistry 12 20%
Psychology 9 15%
Social Sciences 4 7%
Biochemistry, Genetics and Molecular Biology 3 5%
Neuroscience 3 5%
Other 9 15%
Unknown 20 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2016.
All research outputs
#6,042,566
of 22,807,037 outputs
Outputs from Neuropsychiatric Disease and Treatment
#763
of 2,984 outputs
Outputs of similar age
#70,866
of 264,341 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#25
of 71 outputs
Altmetric has tracked 22,807,037 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 2,984 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,341 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.